• Join Today!

Become a member and connect with:

  • An Active Online Community
  • Articles and Advice on SCD
  • Help Understanding Clinical Trials
healthcare providers

Jeffrey Lebensburger, MD

Healthcare Provider
Director of Pediatric Hematology Section
UAB Division of Hematology and Oncology
Children's of Alabama
1600 7th Ave. S.
Lowder Bldg., Suite 512
Birmingham, Alabama, United States

Dr. Lebensburger is a graduate of the University of Pennsylvania for undergraduate training and the Nova Southeastern Medical School. After his pediatric residency at Arnold Palmer Hospital for Children in Orlando, Florida, Dr. Lebensburger completed fellowship training in Pediatric Hematology Oncology at St. Jude Children’s Research Hospital. His primary clinical focus involves caring for children with blood disorders, including sickle cell disease, thalassemia, bleeding disorders, disorders of iron metabolism, and marrow failure syndromes.

In addition to his clinical care, Dr. Lebensburger focuses on linking knowledge from basic science to clinical care (translational research) especially in sickle cell disease. Currently, Dr. Lebensburger is the primary investigator for two prestigious research grants from the National Institutes of Health and American Society of Hematology to better understand kidney disease in patients with sickle cell disease. While pain is the hallmark clinical complication of sickle cell disease, many young adult patients suffer from early development of kidney failure.


Representative Publications:

Evaluating risk factors for chronic kidney disease in pediatric patients with sickle cell anemia

Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study

Acute kidney injury during a pediatric sickle cell vaso-occlusive pain crisis

Cranial epidural hematomas: A case series and literature review of this rare complication associated with sickle cell disease

Hydroxycarbamide for patients with silent cerebral infarcts: outcomes and patient preference

Elective cholecystectomy reduces morbidity of cholelithiasis in pediatric sickle cell disease

expertly curated content related to this topic

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.